Thrombotic Microangiopathies and the Linkage between von Willebrand Factor and the Alternative Complement Pathway^[*]

Abstract

Molecular linkages between von Willebrand factor (VWF) and the alternative complement pathway (AP) have recently been discovered. Endothelial cell (EC)-anchored ultra-large (UL) VWF multimeric strings function as an activating surface for the AP. C3 (in active C3b form) binds to the EC-anchored ULVWF strings, and promotes the assembly of C3bBb (C3 convertase) and C3bBbC3b (C5 convertase). These linkages may help to explain enigmatic clinical problems related to thrombotic microangiopathies, including some cases of refractory thrombotic thrombocytopenic purpura (TTP), TTP associated with only mild–modest deficiencies of ADAMTS-13, the provocation (or exacerbation) of acute episodes in patients with the atypical hemolytic uremic syndrome, and thrombosis in paroxysmal nocturnal hemoglobinuria. Recent experiments have also demonstrated that complement factor H performs a dual role: participating in regulation of the AP by binding to EC-anchored ULVWF strings; and functioning as a reductase to decrease the size of soluble VWF multimers.

Keywords

VWF - alternative complement pathway - factor H - thrombotic microangiopathies

^* This article is dedicated to Prof. Duane Schultz of the University of Miami School of Medicine with gratitude for his continuing friendship and for his kind and careful instruction in complement biochemistry.

• References

• 1 Favaloro EJ. Hemolytic uremic syndrome. Preface. Semin Thromb Hemost 2010; 36 (6) 573-574
• 2 Riedl M, Orth-Höller D, Würzner R. An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 2014; 40: 413-415
• 3 Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS ONE 2013; 8 (3) e59372
• 4 Turner N, Nolasco L, Moake J. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. Semin Thromb Hemost 2012; 38 (1) 38-46
• 5 Nolasco L, Nolasco J, Feng S, Afshar-Kharghan V, Moake J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers—brief report. Arterioscler Thromb Vasc Biol 2013; 33 (11) 2524-2528
• 6 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 (8) 589-600
• 7 Furlan M, Robles R, Galbusera M , et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339 (22) 1578-1584
• 8 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89 (9) 3097-3103
• 9 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
• 10 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6 (1) 60
• 11 Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31 (6) E1445-E1460
• 12 Zipfel PF, Edey M, Heinen S , et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3 (3) e41
• 13 Frémeaux-Bacchi V, Miller EC, Liszewski MK , et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112 (13) 4948-4952
• 14 Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J , et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104 (1) 240-245
• 15 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365 (1-2) 8-26
• 16 Law SK, Levine RP. Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci U S A 1977; 74 (7) 2701-2705
• 17 Pangburn MK, Ferreira VP, Cortes C. Discrimination between host and pathogens by the complement system. Vaccine 2008; 26 (8) (Suppl. 08) I15-I21
• 18 Law SK, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997; 6 (2) 263-274
• 19 Schreiber RD, Pangburn MK, Lesavre PH, Müller-Eberhard HJ. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A 1978; 75 (8) 3948-3952
• 20 Fearon DT, Austen KF, Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med 1973; 138 (6) 1305-1313
• 21 Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954; 120 (3112) 279-285
• 22 Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 1976; 73 (9) 3268-3272
• 23 Kinoshita T, Takata Y, Kozono H, Takeda J, Hong KS, Inoue K. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol 1988; 141 (11) 3895-3901
• 24 Rawal N, Pangburn M. Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol 2001; 166 (4) 2635-2642
• 25 Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104 (1) 100-106
• 26 Huang J, Motto DG, Bundle DR, Sadler JE. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood 2010; 116 (18) 3653-3659
• 27 Nolasco LH, Turner NA, Bernardo A , et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106 (13) 4199-4209
• 28 Klegeris A, Bissonnette CJ, Dorovini-Zis K, McGeer PL. Expression of complement messenger RNAs by human endothelial cells. Brain Res 2000; 871 (1) 1-6
• 29 Langeggen H, Berge KE, Macor P , et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. APMIS 2001; 109 (1) 73-78
• 30 Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121 (1) 69-76
• 31 Würzner R, Joysey VC, Lachmann PJ. Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J Immunol 1994; 152 (9) 4624-4629
• 32 Cines DB, Pollak ES, Buck CA , et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91 (10) 3527-3561
• 33 Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264 (15) 9053-9060
• 34 Réti M, Farkas P, Csuka D , et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10 (5) 791-798
• 35 Ruiz-Torres MP, Casiraghi F, Galbusera M , et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93 (3) 443-452
• 36 Chapin J, Weksler B, Magro C, Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157 (6) 772-774
• 37 Tsai E, Chapin J, Laurence JC, Tsai HM. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013; 162 (4) 558-559
• 38 Feng S, Eyler SJ, Zhang Y , et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 2013; 122 (8) 1487-1493
• 39 Sartz L, Olin AI, Kristoffersson AC , et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012; 188 (4) 2030-2037
• 40 Delvaeye M, Noris M, De Vriese A , et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (4) 345-357
• 41 Endo M, Ware RE, Vreeke TM , et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood 1996; 87 (6) 2546-2557
• 42 Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84 (1) 7-17
• 43 Yamashina M, Ueda E, Kinoshita T , et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323 (17) 1184-1189
• 44 Savage WJ, Barber JP, Mukhina GL , et al. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol 2009; 37 (1) 42-51
• 45 Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144 (9) 3478-3483
• 46 Cole JL, Housley Jr GAJ, Dykman TR, MacDermott RP, Atkinson JP. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U S A 1985; 82 (3) 859-863
• 47 Seya T, Atkinson JP. Functional properties of membrane cofactor protein of complement. Biochem J 1989; 264 (2) 581-588
• 48 Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121 (25) 4985-4996 , quiz 5105
• 49 Studt JD, Kremer Hovinga JA, Antoine G , et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105 (2) 542-544
• 50 Frimat M, Tabarin F, Dimitrov JD , et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013; 122 (2) 282-292
• 51 Grünewald M, Grünewald A, Schmid A , et al. The platelet function defect of paroxysmal nocturnal haemoglobinuria. Platelets 2004; 15 (3) 145-154
• 52 Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 2009; 114 (24) 5102-5111
• 53 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78 (6) 1456-1461
• 54 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
• 55 Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83 (8) 2171-2179
• 56 Ripoche J, Day AJ, Harris TJ, Sim RB. The complete amino acid sequence of human complement factor H. Biochem J 1988; 249 (2) 593-602